Corrigendum to: “High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention” [Early Human Development 88S2 (2012) S34–S41]

Invasive Candida infections (ICI) have a high burden of morbidity and mortality in the neonatal setting. Although the identification of effective prophylactic strategies has recently led to the prevention of many episodes of systemic fungal disease, the identification of effective treatment strategies is still a priority. The correct choice of the most appropriate antifungal drug for treatment of such infections requires specific expertise, as well as careful consideration of a number of variables related both to the characteristics of the patient and to the peculiarities of these infections in neonates. The ideal antifungal drug for preterm neonates should have a good ability to target fungal biofilms, in order to prevent or improve the course of end-organ localisations. It should also be active against fluconazole-resistant species, as well as safe enough to be used with no or limited interference with other neonatal drugs. In this view, the echinocandin class of antifungal agents has recently proven to be a suitable option for treatment. However, further studies are warranted to better establish kinetics and appropriate dosing of these agents in premature and term infants, as well as their ability to improve late outcomes of ICI.

Corrigendum to: “High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention” [Early Human Development 88S2 (2012) S34–S41] Journal Articles